Table of Content
LONDON. Process for the “guidance” of the human immune system so that it kills cancer cells found British scientists.
The new method described in a publication in the journal Science, identifying unique markings inside tumors, which can be used as “targets” by the immune system.
Although promising, this method is expected to be very costly, as it requires a special design for each patient and has not yet been tested in humans. Experts recognize the logic of the process, however, warn that the implement is still far.
The idea of guiding the immune system to fight tumors is not new, and previous cancer vaccine development efforts proved premature, vaccines fail in clinical trials. One explanation for these failures is that vaccines guide the body’s defenses at the wrong target.
The problem lies in the fact that the tumors do not consist of the same cells, but patchwork heavy mutant cells and tissue samples from different parts of the same volume can be varied widely and react quite differently in various therapies.
Cancerous tumor cells grow in a manner reminiscent of the trees, with initial mutations in the core (torso) and different mutations in their branches (the branches). This phenomenon is known as the heterogeneity of the tumor cells.
Professor Charles Souonton, of the UCL Cancer Institute in London explains:stick to the surface of cancer cells.
This is the Achilles heel of all these highly complex cancers. Our study leads to the boundaries of personalized medical care, each patient to ensure treatment
The targeting mutations to the antigen. The first is the development of vaccines for each patient, able to “educate” the immune system so that it detects mutations antigens. The second approach is the “fishing” of the immune cells which already targeting these mutations. The these immune cells may be cultured immediately to a laboratory, to be injected back into the patient.
The authors believe that their work can be the basis for developing new therapies, while expressing the hope that clinical trials can begin within the next two years.
“Our research makes us think seriously about the heterogeneity and because it offers cancer so big advantage,” says Dr. Mark Gkerlingker of UCL.